Mechanisms of Semaglutide Therapy in Heart Failure Patients
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: inflammation, cardiovascular, cancer
- Who it enrolls
- age 20 Years to 80 Years; excludes diabetes; no BMI minimum stated; conditions: Heart Failure; Obesity
- Interventions
- Semaglutide
- Conditions
- Heart Failure; Obesity
- Phase and size
- Phase 1, Phase 2 · 10 participants
- Dates
- Start 2024-07-10
Primary completion 2025-07-10 - Sponsor
- University Medical Centre Ljubljana (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Interleukin-6 (IL-6)4 months
- Interleukin-8 (IL-8)4 months
- Tumor Necrosis Factor-alpha (TNF-α)4 months
- Interferon-gamma (IFN-γ)4 months
- B-type Natriuretic Peptide (BNP)4 months
- C-reactive Protein (CRP)4 months
- Hemoglobin A1C (HgA1C)4 months
- Complete Blood Count (CBC)4 months
- Comprehensive Metabolic Panel (Chem 7)4 months
- Liver Function Tests (LFT)4 months
- Body mass index4 months
02Eligibility
Who can take part
Inclusion Criteria: * Age: 20-80 years * Presence of heart failure * Body-mass index 27 kg/m2 or greater * Stable optimally tolerated dosages of heart failure therapies for 3 months * N-terminal pro B-type natriuretic peptide levels \>350 pg/mL Exclusion Criteria: * Presence of type 1 or type 2 diabetes or glycated haemoglobin higher than 6.5% * Pregnancy or potential to become pregnant * Cancer * Liver dysfunction (aspartate aminotransferase and/or alanine aminotransferase \> 3 times upper limits of normal or total bilirubin greater than 1.5 times upper limits of normal) * Renal dysfunction (estimated glomerular filtration rate less than 25 mL/min/1.73 m2) * Hospitalization in the past 3 months for reasons other than heart failure * New York Heart Association (NYHA) functional class I or functional class IV symptoms. * Prior or planned bariatric surgery * Self-reported change in body weight \>11 lbs (5 kg) within 3 months before enrollment * Acute or chronic infection
03Change log
Registry changes
No changes recorded since the trial was added.